Get started
Author

Wolfram Brugger

Institution: RWE (Germany)
Observed institution: RWE (Germany)
ORCID: 0009-0000-8537-0577
Observed ORCID: 0009-0000-8537-0577
OpenAlex ID: A5140918267
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
2026 · Max S. Topp, Bijal D. Shah, et al. · Leukemia
PDF
Figure 2 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 5 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S5 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Data from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Figure S1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S6 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S2 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 4 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S4 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Table 1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al. · Cancer Research Communications
The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD).
2026 · Jae Hong Park, Karamjeet S. Sandhu, et al. · Journal of Clinical Oncology
LBS1:02 CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel (obe-cel), in severe refractory systemic lupus erythematosus (srSLE): initial results from phase I CARLYSLE study
2026 · Maria Leandro, Ruth Pepper, et al. · Lupus Science & Medicine
PDF
Chimeric Antigen Receptor (CAR) T-cell Persistence at Month 3 (M3) Predicts Clinical Outcomes in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene autoleucel (obe-cel)
2026 · Claire Roddie, Jae H Park, et al. · Transplantation and Cellular Therapy
Treatment of Pediatric Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia with Obecabtagene autoleucel, a CD19-Directed Chimeric Antigen Receptor T-cell Therapy: Preliminary Findings from the Phase Ib/II CATULUS Trial
2026 · Sara Ghorashian, Michael A Pulsipher, et al. · Transplantation and Cellular Therapy
Works count: 20
Citation count:
H-index:
I10-index:
Year
Topic
Type